


PHARMACEUTICAL 2022

Kura Oncology Inc. Rank 59 of 466







PHARMACEUTICAL 2022



Kura Oncology Inc. Rank 59 of 466

The relative strengths and weaknesses of Kura Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kura Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 66% points. The greatest weakness of Kura Oncology Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 264%, being 186% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	522,289
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,455
Liabilities, Non-Current	4,987
Other Assets	9,089
Other Compr. Net Income	-1,835
Other Expenses	0
Other Liabilities	0
Other Net Income	792
Other Revenues	0
Property and Equipment	2,673
Research and Development	84,721
Selling, General and Administrative Expense	46,537

Output Variable	Value in 1000 USD
Assets	534,051
Liabilities	27,442
Expenses	131,258
Revenues	0
Stockholders Equity	506,609
Net Income	-130,466
Comprehensive Net Income	-131,384
Economic Capital Ratio	264%

